Physician profile
Robert M Evans
NPI 1255349502
$8,045.51
in general payments reported to CMS, 2019-2025
41 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,249 · 2020: $2,581 · 2021: $1,630 · 2022: $412 · 2023: $53.80 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,101.51 | 2019-2021 | |
| Novo Nordisk INC | $1,045.15 | 2019-2025 | Wegovy |
| Amgen INC. | $816.01 | 2019-2021 | |
| Lilly USA, LLC | $580.42 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $571.54 | 2019-2023 | Cycloset |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.41 | 2019-2021 | |
| Insulet Corporation | $501.83 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $428.97 | 2019-2021 | |
| Abbott Laboratories | $409.97 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $308.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $249.56 | 2019-2021 | |
| Esperion Therapeutics, INC. | $189.80 | 2020-2021 | |
| Dexcom, INC. | $127.94 | 2019-2021 | |
| Shire North American Group INC | $112.73 | 2019 | |
| Valeritas, INC. | $102.92 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.